Table 5. Comparison of miRNA expression levels between healthy controls and invasive BC patients (stratified by clinical characteristics).
| Fold change | P value | Fold change | P value | Fold change | P value | |
|---|---|---|---|---|---|---|
| LNM | LNM negative vs. Controls | LNM positive vs. Controls | LNM positive vs. LNM negative | |||
| miR-19a | 0.75 | 0.552 | 0.32 | 0.032 | 0.42 | 0.046 |
| miR-20a | 0.38 | 0.073 | 0.27 | 0.024 | 0.72 | 0.458 |
| miR-27a | 0.23 | <0.001 | 0.19 | <0.001 | 0.84 | 0.557 |
| G (grade) | G1 and G2 vs. Controls | G3 vs. Controls | G3 vs. G1 and G2 | |||
| miR-17 | 0.77 | 0.364 | 0.28 | 0.009 | 0.36 | 0.007 |
| miR-18a | 1.47 | 0.445 | 0.67 | 0.494 | 0.46 | 0.045 |
| miR-20a | 0.43 | 0.110 | 0.26 | 0.025 | 0.61 | 0.136 |
| miR-27a | 0.26 | 0.001 | 0.17 | <0.001 | 0.66 | 0.674 |
| HR status | HR positive vs. Controls | HR negative vs. Controls | HR positive vs. HR negative | |||
| miR-17 | 0.61 | 0.159 | 0.21 | 0.010 | 0.35 | 0.023 |
| miR-20a | 0.37 | 0.042 | 0.29 | 0.060 | 0.78 | 0.817 |
| miR-27a | 0.23 | <0.001 | 0.14 | <0.001 | 0.58 | 0.303 |
| miR-155 | 0.62 | 0.181 | 1.42 | 0.324 | 2.34 | 0.022 |
| HER2 status | HER2 normal vs. Controls | HER2 amplified vs. Controls | HER2 amplified vs. HER2 normal | |||
| miR-17 | 0.54 | 0.143 | 0.30 | 0.046 | 0.55 | 0.085 |
| miR-20a | 0.37 | 0.033 | 0.24 | 0.033 | 0.63 | 0.265 |
| miR-27a | 0.24 | <0.001 | 0.12 | <0.001 | 0.50 | 0.238 |
| Ki-67 expression | Ki-67 low vs. Controls | Ki-67 high vs. Controls | Ki-67 high vs. Ki-67 low | |||
| miR-17 | 0.62 | 0.315 | 0.32 | 0.017 | 0.52 | 0.080 |
| miR-20a | 0.42 | 0.105 | 0.25 | 0.016 | 0.60 | 0.159 |
| miR-27a | 0.22 | <0.001 | 0.20 | <0.001 | 0.89 | 0.673 |
| miR-155 | 0.58 | 0.247 | 1.01 | 0.786 | 1.74 | 0.039 |
| CTC positivity | CTC negative vs. Controls | CTC positive vs. Controls | CTC positive vs. CTC negative | |||
| miR-20a | 0.42 | 0.112 | 0.26 | 0.023 | 0.62 | 0.137 |
| miR-27a | 0.23 | <0.001 | 0.20 | 0.001 | 0.88 | 0.695 |
Only miRNAs significantly up- or down-regulated are listed. P values shown in bold indicate statistical significance of the expression level. Analysis of statistical significance was applied to the ΔCt values. The numbers of invasive BC patients and controls included in the study were 128 and 28, respectively. For each miRNA, only samples analyzed successfully were included into statistical analysis.
LMN, lymph node metastasis; G1, G2 and G3, Grade 1, 2 and 3, respectively; HR, hormonal (estrogen and/or progesterone) receptor; HER2, erb-b2 receptor tyrosine kinase 2; Ki-67, Ki-67 proliferation marker; CTC, circulating tumor cells.